The phosphodiesterase type 4 inhibitor, rolipram, enhances glucocorticoid receptor function

Neuropsychopharmacology

Volumn 27, Issue 6, 2002, Pages 939-948

  Miller, Andrew H ^a   Vogt, Gerald J ^a   Pearce, Bradley D ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressants; Autoimmune disorders; cAMP; Depression; Hypothalamic pituitary adrenal axis; Mood disorders; Multiple drug resistance pump; Tumor necrosis factor alpha

Indexed keywords

DESIPRAMINE; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; MIFEPRISTONE; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL FUNCTION; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; GENE TRANSLOCATION; GENETIC TRANSFECTION; GLIOMA CELL; HORMONE BINDING; HORMONE INHIBITION; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; RECEPTOR BINDING; REPORTER GENE; STATISTICAL ANALYSIS;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; MICE; PHOSPHODIESTERASE INHIBITORS; RATS; RECEPTORS, GLUCOCORTICOID; ROLIPRAM;

EID: 0036899099     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(02)00381-0     Document Type: Article

References (53)

1. Abbas N., Zou L.P., Pelidou S.H., Winblad B., Zhu J. Protective effect of Rolipram in experimental autoimmune neuritis. protection is associated with down-regulation of IFN-gamma and inflammatory chemokines as well as up-regulation of IL-4 in peripheral nervous system Autoimmunity. 32:2000;93-99.
2. Beavo J.A., Conti M., Heaslip R.J. Multiple cyclic nucleotide phosphodiesterases. Mol Pharmacol. 46:1994;399-405.
3. Beshay E., Croze F., Prud'homme G.J. The phosphodiesterase inhibitors pentoxifylline and rolipram suppress macrophage activation and nitric oxide production in vitro and in vivo. Clin Immunol. 98:2001;272-279.
4. Bobon D., Breulet M., Gerard-Vandenhove M.-A., Guito-Goffioul F., Plomteux G., Satre-Hernandez M., Schratzer M., Troisfontaines B., von Frenckell R., Wachtel H. Is phosphodiesterase inhibitor a new mechanism of antidepressant action? Eur Arch Psychiatr Neurol Sci. 238:1988;2-6.
5. Chen J., Rasenick M.M. Chronic treatment of C6 glioma cells with antidepressant drugs increases functional coupling between a G protein (Gs) and adenylyl cyclase. J Neurochem. 64:1995;724-732. a.
6. Chen J., Rasenick M.M. Chronic antidepressant treatment facilitates G protein activation of adenylyl cyclase without altering G protein content. J Pharmacol Exp Ther. 275:1995;509-517. b.
7. Colangelo A.M., Follesa P., Mocchetti I. Differential induction of nerve growth factor and basic fibroblast growth factor mRNA in neonatal and aged rat brain. Brain Res Mol Brain Res. 53:1998;218-225.
8. Daynes R.A., Araneo B.A. Contrasting effects of glucocorticoids on the capacity of T cells to produce the growth factors interleukin 2 and interleukin 4. Eur J Immunol. 19:1989;2319-2325.
9. Eckmann F., Fichte K., Meya U., Sastre-Y-Hernandez M. Rolipram in major depression. results of a double blind comparative study with amitriptyline Current Therapeutic Res. 43:1988;291-295.
10. Eickelberg O., Roth M., Lorx R., Bruce V., Rudiger J., Johnson M., Block L.-H. Ligand-independent activation of the glucocorticoid receptor by Beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem. 274:1999;1005-1010.
11. Eigler A., Siegmund B., Emmerich U., Baumann K.H., Hartmann G., Endres S. Anti-inflammatory activities of cAMP-elevating agents. enhancement of IL-10 synthesis and concurrent suppression of TNF production J Leukoc Biol. 63:1998;101-107.
12. Engels P., Fichtel K., Lübbert H. Expression and regulation of human and rat phosphodiesterase type 4 isogenes. FEBS Lett. 350:1994;291-295.
13. Follesa P., Mocchetti I. Regulation of basic fibroblast growth factor and nerve growth factor mRNA by beta-adrenergic receptor activation and adrenal steroids in rat central nervous system. Mol Pharmacol. 43:1993;132-138.
14. Gayo A., Mozo L., Suarez A., Tunon A., Lahoz C., Gutierrez C. Glucocorticoids increase IL-10 expression in multiple sclerosis patients with acute relapse. J Neuroimmunol. 85:1998;122-130.
15. Grundy P.L., Patel N., Harbuz M.S., Lightman S.L., Sharples P.M. Glucocorticoids modulate the NGF mRNA response in the rat hippocampus after traumatic brain injury. Brain Res. 892:2001;386-390.
16. Hayes V.Y., Isackson P.J., Fabrazzo M., Follesa P., Mocchetti I. Induction of nerve growth factor and basic fibroblast growth factor mRNA following clenbuterol. contrasting anatomical and cellular localization Exp Neurol. 132:1995;33-41.
17. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology. 23:2000;477-501.
18. Holsboer F., Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr Rev. 17:1996;187-205.
19. Kent S., Bluthe R.M., Kelley K.W., Dantzer R. Sickness behavior as a new target for drug development. Trends Pharmacol Sci. 13:1992;24-28.
20. Kung T.T., Crawley Y., Luo B., Young S., Kreutner W., Chapman R.W. Inhibition of pulmonary eosinophilia and airway hyperresponsiveness in allergic mice by rolipram. involvement of endogenously released corticosterone and catecholamines Br J Pharmacol. 130:2000;457-463.
21. Laemont K.D., Schaefer C.J., Juneau P.L., Schrier D.J. Effects of the phosphodiesterase inhibitor rolipram on streptococcal cell wall-induced arthritis in rats. Int J Immunopharmacol. 21:1999;711-725.
22. Maes M. Major depression and activation of the inflammatory response system. Adv Exp Med Biol. 461:1999;25-46.
23. Mahler M.E. Behavioral manifestations associated with multiple sclerosis. Psychiatr Clin North Am. 15:1992;427-438.
24. Miller A.H., Pariante C.M., Pearce B.D. Effects of cytokines on glucocorticoid receptor expression and function. glucocorticoid resistance and relevance to depression Adv Exp Med Biol. 461:1999;107-116.
25. Miller A.H., Spencer R.L., Pulera M., Kang S., McEwen B.S., Stein M. Adrenal steroid receptor activation in rat brain and pituitary following dexamethasone. implications for the dexamethasone suppression test Biol Psychiatry. 32:1992;850-869.
26. Mocchetti I., Spiga G., Hayes V.Y., Isackson P.J., Colangelo A. Glucocorticoids differentially increase nerve growth factor and basic fibroblast growth factor expression in the rat brain. J Neurosci. 16:1996;2141-2148.
27. Moran M.G. Psychiatric aspects of rheumatology. Psychiatr Clin North Am. 19:1996;575-587.
28. Musselman D.L., Miller A.H., Porter M.R., Manatunga A., Gao F., Penna S., Pearce B.D., Landry J., Glover S., McDaniel J.S., Nemeroff C.B. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression. preliminary findings Am J Psychiatry. 158:2001;1252-1257.
29. Nestler E.J., Terwilliger R.Z., Duman R.S. Chronic antidepressant administration alters the subcellular distribution of cyclic AMP-dependent protein kinase in rat frontal cortex. J Neurochem. 53:1989;1644-1647.
30. Nibuya M., Nestler E.J., Duman R.S. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci. 16:1996;2365-2372.
31. Nordeen S.K., Bona B.J., Moyer M.L. Latent agonist activity of the steroid antagonist, RU486, is unmasked in cells treated with activators of protein kinase A. Mol Endocrinol. 7:1993;731-742.
32. Owens MJ, Nemeroff CB (1993): The role of CRF in the pathophysiology of affective disorders: Laboratory and clinical studies. In Vale WW (ed), Ciba Foundation Symposium on Corticotropin-Releasing Factor, 172. New York, John Wiley & Sons, pp 293-316.
33. Pang L., Knox A.J. Synergistic inhibition by beta(2)-agonists and corticosteroids on tumor necrosis factor-alpha-induced interleukin-8 release from cultured human airway smooth-muscle cells. Am J Respir Cell Mol Biol. 23:2000;79-85.
34. Pang L., Knox A.J. Regulation of TNF-alpha-induced eotaxin release from cultured human airway smooth muscle cells by beta2-agonists and corticosteroids. FASEB J. 15:2001;261-269.
35. Pariante C.M., Makoff A., Lovestone S., Feroli S., Heyden A., Miller A.H., Kerwin R.W. Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transporters. Br J Pharmacol. 134:2001;1335-1343. a.
36. Pariante C.M., Miller A.H. Glucocorticoid receptors in depression. relevance to pathophysiology and treatment Biol Psychiatry. 49:2001;391-404.
37. Pariante C.M., Pearce B.D., Pisell T.L., Owens M.J., Miller A.H. Steroid-independent translocation of the glucocorticoid receptor by the antidepressant desipramine. Mol Pharmacol. 52:1997;571-581.
38. Pariante C.M., Pearce B.D., Pisell T.L., Sanchez C.I., Po C., Su C., Miller A.H. The proinflammatory cytokine, interleukin-1 alpha, reduces glucocorticoid receptor translocation and function. Endocrinology. 140:1999;4359-4366.
39. Pariante C.M., Pearce B.D., Pisell T.L., Su C., Miller A.H. The steroid receptor antagonists, RU40555 and RU486, activate glucocorticoids receptor translocation and are not excreted by the steroid hormones transporter in L929 cells. J Endocrinol. 169:2001;309-320. b.
40. Perez-Torres S., Miro X., Palacios J.M., Cortes R., Puigdomenech P., Mengod G. Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and[3H]rolipram binding autoradiography. Comparison with monkey and rat brain. J Chem Neuroanat. 20:2000;349-374.
41. Rangarajan P.N., Umesono K., Evans R.M. Modulation of glucocorticoid receptor function by protein kinase A. Mol Endocrinol. 6:1992;1451-1457.
42. Ross S.E., Williams R.O., Mason L.J., Mauri C., Marinova-Mutafchieva L., Malfait A.M., Maini R.N., Feldmann M. Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram. J Immunol. 159:1997;6253-6259.
43. Sato A., Sheppard K.E., Fullerton M.J., Funder J.W. cAMP modulates glucocorticoid-induced protein accumulation and glucocorticoid receptor in cardiomyocytes. Am J Physiol. 271:1996;E827-E833.
44. Schmidt P., Holsboer F., Spengler D. 2-adrenergic receptors potentiate glucocorticoid receptor transactivation via G protein [beta][gamma]-subunits and the phosphoinositide 3-kinase pathway. Mol Endocrinol. 15:2001;553-564. [beta].
45. Sekut L., Yarnall D., Stimpson S.A., Noel L.S., Bateman-Fite R., Clark R.L., Brackeen M.F., Menius J.A. Jr., Connolly K.M. Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation. Clin Exp Immunol. 100:1995;126-132.
46. Sharom F.J. The P-glycoprotein efflux pump. how does it transport drugs? J Membr Biol. 160:1997;161-175.
47. Sommer N., Martin R., McFarland H.F., Quigley L., Cannella B., Raine C.S., Scott D.E., Loschmann P.A., Racke M.K. Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease. J Neuroimmunol. 79:1997;54-61.
48. Sternberg E.M. Neuroendocrine regulation of autoimmune/inflammatory disease. J Endocrinol. 169:2001;429-435.
49. Swain M.G., Appleyard C., Wallace J., Wong H., Le T. Endogenous glucocorticoids released during acute toxic liver injury enhance hepatic IL-10 synthesis and release. Am J Physiol. 276:1999;G199-G205.
50. Wachtel H., Schneider H.H. Rolipram, a novel antidepressant drug, reverses the hypothermia and hypokinesia of monoamine-depleted mice by an action beyond postsynaptic monoamine receptors. Neuropharmacology. 25:1986;1119-1126.
51. Yamamoto M., Sobue G., Li M., Arakawa Y., Mitsuma T., Kimata K. Nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) and low-affinity nerve growth factor receptor (LNGFR) mRNA levels in cultured rat Schwann cells; differential time- and dose-dependent regulation by cAMP. Neurosci Lett. 152:1993;37-40.
52. Yang Y.H., Hutchinson P., Santos L.L., Morand E.F. Glucocorticoid inhibition of adjuvant arthritis synovial macrophage nitric oxide production. role of lipocortin 1 Clin Exp Immunol. 111:1998;117-122.
53. Zhu J., Mix E., Winblad B. The antidepressant and anti-inflammatory effects of rolipram in the central nervous system. CNS Drug Rev. 7:2001;387-398.